USAResearch and clinical trials
Experimental sevasemten in Becker muscular dystrophy: well tolerated over 2 years in 12 adults
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
In the USA, 12 adults with Becker muscular dystrophy took sevasemten, an experimental drug, for 24 months. The drug is given by mouth once a day. No serious side effects were seen, and no patient stopped the drug because of side effects. Blood markers of muscle damage fell, and walking function remained stable over the 24 months.
What does it mean for patients and families?
This is a small early-stage study without a placebo group. Larger studies must show whether the drug really works. The drug is not yet approved.
Source
Scientific paper: Effects of sevasemten (EDG-5506) on safety, biomarkers, and functional measures in adults with Becker muscular dystrophy: results of a phase 1b, open-label study. EBioMedicine, 2026. DOI: 10.1016/j.ebiom.2026.106335 · PubMed 42308588
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Becker muscular dystrophy (BMD)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.